Idioma:

Superion interspinous process spacer for intermittent neurogenic claudication secondary to moderate lumbar spinal stenosis: two-year results from a randomized controlled FDA-IDE pivotal trial

Patel, Vikas V ; Whang, Peter G ; Haley, Thomas R ; Bradley, W Daniel ; Nunley, Pierce D ; Davis, Raphael P ; Miller, Larry E ; Block, Jon E ; Geisler, Fred H

Spine (Philadelphia, Pa. 1976), 2015-03, Vol.40 (5), p.275-282 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por

Enviar para

Título:
Superion interspinous process spacer for intermittent neurogenic claudication secondary to moderate lumbar spinal stenosis: two-year results from a randomized controlled FDA-IDE pivotal trial
Autor: Patel, Vikas V ; Whang, Peter G ; Haley, Thomas R ; Bradley, W Daniel ; Nunley, Pierce D ; Davis, Raphael P ; Miller, Larry E ; Block, Jon E ; Geisler, Fred H
Assuntos: Aged ; Aged, 80 and over ; Decompression, Surgical - instrumentation ; Decompression, Surgical - methods ; Female ; Humans ; Intermittent Claudication - diagnosis ; Intermittent Claudication - etiology ; Intermittent Claudication - surgery ; Internal Fixators - standards ; Lumbar Vertebrae - pathology ; Lumbar Vertebrae - surgery ; Male ; Middle Aged ; Prospective Studies ; Prostheses and Implants ; Spinal Stenosis - complications ; Spinal Stenosis - diagnosis ; Spinal Stenosis - surgery ; Therapies, Investigational ; United States ; United States Food and Drug Administration
É parte de: Spine (Philadelphia, Pa. 1976), 2015-03, Vol.40 (5), p.275-282
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-News-2
ObjectType-Feature-3
content type line 23
Descrição: Prospective, multicenter, randomized, controlled, investigational device exemption noninferiority trial. To determine 2-year outcomes in patients with intermittent neurogenic claudication secondary to moderate lumbar spinal stenosis (LSS) who were treated with the Superion interspinous process spacer. Interspinous spacers are a less-invasive treatment alternative compared with surgical decompression for patients with LSS unresponsive to conservative care. High-quality comparative data with these devices are lacking. Patients presenting with intermittent neurogenic claudication secondary to moderate LSS who failed at least 6 months of nonsurgical management were randomly allocated to treatment with the Superion spacer or a control spacer (X-Stop) and followed for 2 years. A total of 391 randomized patients were implanted with Superion (n = 190) or control (n = 201) spacers at 29 sites in the United States between August 2008 and December 2011. Implants were successfully implanted in 99.5% of patients with Superion and 99.0% of control patients. The primary composite endpoint of this study was met, which demonstrated that the Superion spacer was noninferior to the X-Stop spacer. Leg pain, the predominant patient complaint, decreased in severity by 70% during 2 years in each group. Most (77%) patients achieved leg pain clinical success (improvement ≥20 mm) at 2 years. Back pain clinical success (improvement ≥20 mm) was 68%, with no differences between groups. Oswestry Disability Index clinical success (≥15% point improvement) was achieved in 65% of patients. The rates of complications and reoperations were similar between groups. The Superion interspinous process spacer relieves symptoms of intermittent neurogenic claudication secondary to moderate LSS in the majority of patients through 2 years. 2.
Editor: United States
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Superion interspinous process spacer for intermittent neurogenic claudication secondary to moderate lumbar spinal stenosis: two-year results from a randomized controlled FDA-IDE pivotal trial

Patel, Vikas V ; Whang, Peter G ; Haley, Thomas R ; Bradley, W Daniel ; Nunley, Pierce D ; Davis, Raphael P ; Miller, Larry E ; Block, Jon E ; Geisler, Fred H

United States

Buscando em bases de dados remotas. Favor aguardar.